Evaluation of the AIVARIX in Detecting Signs C 1-2 Classes of CVD
該当なし
完了
NCT05612217
| 対象疾患 | Chronic Venous Disease, CVD |
|---|
| 相 | 該当なし |
|---|
| スポンサー | Servier Russia |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 433 名 |
|---|
| 介入（薬剤） | to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD |
|---|
| 開始日 | 2022年12月1日 |
|---|
| 完了日 | 2023年6月1日 |
|---|
| 結果公開日 | 2024年9月25日 |
|---|
概要
This study is a multicenter observational study, which is carried out in frame of routine clinical practice in Russia. The program will include patients suggestive to chronic venous diseases (CVDs) including but not limited to those with C1 and C2 classes by CEAP classification, who will be seeking professional phlebologists' consultation. Study conduction is scheduled in Russia in 2022-2023. The planned number of patients is 414
Evaluation of Sensitivity (Sn) of the AI-based AIVARIX App in Detecting C1 and C2 Classes of CVD in Patients Who Are Seeking for Professional Advice From a Phlebologist Regarding Symptoms and Signs Suggestive to CVD.
1 month · percentage of of positive cases
| Patients With CVD | 75.19 percentage of of positive cases |
|---|
Evaluation of Specificity (Sp) of the AI-based AIVARIX App in Detecting C1 and C2 Classes of CVD in Patients Who Are Seeking for Professional Advice From a Phlebologist Regarding Symptoms and Signs Suggestive to CVD
1 month · percentage of negative cases
| Patients With CVD | 86.51 percentage of negative cases |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。